Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698158 | 0.85 | PTGDR2 (0.49) | ALDH1A1KDM4EGAAHSD17B10PTGDR2 | |
| SCHEMBL3422472 | 0.82 | PTGDR2 (0.53) | PTGDR2CYP19A1TSHRADRA2CMEN1 | |
| SCHEMBL29430712 | 0.81 | GABRG2 (0.46) | ALDH1A1KDM4EGAAEGLN2ADORA2A | |
| SCHEMBL28757167 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAHSD17B10ADORA2A | |
| SCHEMBL22636969 | 0.80 | CYP11B2 (0.58) | KDM4EGAAADORA2AADORA1CYP19A1 | |
| SCHEMBL996126 | 0.78 | PTGDR2 (0.50) | ALDH1A1PTGDR2CYP19A1TSHRMEN1 | |
| SCHEMBL5633361 | 0.78 | STS (0.54) | ALDH1A1KDM4EGAAPTGDR2CYP19A1 | |
| SCHEMBL12855308 | 0.78 | PTGDR2 (0.50) | PTGDR2CYP19A1TSHRADRA2CMEN1 | |
| SCHEMBL20740894 | 0.78 | PTGDR2 (0.50) | PTGDR2CYP19A1TSHRADRA2CMEN1 | |
| SCHEMBL31741946 | 0.78 | PTGDR2 (0.50) | ALDH1A1PTGDR2CYP19A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878873-A | Liquid crystal elastic network@liquid metal nanoparticle, preparation method and application | 四川大学 | 2024-11-01 | — | — | CN | claimed |
| CN-115785131-B | Method for synthesizing high-efficiency luminescent complex material with tunable luminescent wavelength | 五邑大学 | 2024-05-17 | — | — | CN | claimed |
| EP-0463931-B1 | Amorphous copolymers, translucent to visible light, for applications in non linear optics | THOMSON CSF (FR) | 1996-04-24 | — | — | EP | claimed |
| CN-118878873-A | Liquid crystal elastic network@liquid metal nanoparticle, preparation method and application | 四川大学 | 2024-11-01 | — | — | CN | disclosed |
| EP-3966196-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020225569-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2020-11-12 | — | — | WO | disclosed |
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| CN-103037969-B | Complex compound | Johnson Matthey Public Co.,Ltd. (GB) | 2015-07-29 | — | — | CN | disclosed |
| WO-2014146994-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| EP-1817288-A4 | DUAL ANTIPLATELET/ANTICOAGULANT PYRIDOXINE ANALOGS | MEDICURE INT INC (BB) | 2009-08-26 | — | — | EP | disclosed |
| EP-1817288-A1 | DUAL ANTIPLATELET/ANTICOAGULANT PYRIDOXINE ANALOGS | Medicure International Inc. (BB) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006050598-A1 | DUAL ANTIPLATELET/ANTICOAGULANT PYRIDOXINE ANALOGS | MEDICURE INTERNATIONAL INC. (CA) | 2006-05-18 | — | — | WO | disclosed |
| US-5547966-A | Aryl urea and related compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-20 | — | — | US | disclosed |
| EP-0463931-B1 | Amorphous copolymers, translucent to visible light, for applications in non linear optics | THOMSON CSF (FR) | 1996-04-24 | — | — | EP | disclosed |
| EP-0656350-A1 | Biaryl urea and related compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| US-5264512-A | Amorphous copolymers, transparent in the visible range, for non-linear optical applications | THOMSON-CSF (FR) | 1993-11-23 | — | — | US | disclosed |
| EP-0463931-A1 | Amorphous copolymers, translucent to visible light, for applications in non linear optics | THOMSON-CSF (FR) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | FABP1, FABP5, FABP2 | ALDH1A1 689/4885KDM4E 3467/4885GAA 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.